Glycosylated pyrazole curcumin derivative as well as preparation method and application thereof

By modifying the structure of curcumin and designing glycosylated pyrazole curcumin derivatives, the stability and water solubility issues of curcumin in clinical applications have been resolved, improving its bioavailability and antitumor activity, and showing broad prospects for clinical application.

CN118955589APending Publication Date: 2024-11-15HEBEI UNIV OF SCI & TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411012211.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Curcumin has problems such as instability in vivo, poor water solubility, and low bioavailability when used clinically, which limits its clinical application.

Method used

By modifying the structure of curcumin to an electron-rich five-membered pyrazole nitrogen heterocycle, and introducing specific oligosaccharide groups into the phenolic hydroxyl group, glycosylated pyrazole curcumin derivatives were designed to improve their water solubility and stability.

Benefits of technology

It significantly improved the water solubility and oil-water partition coefficient of the compound, increased blood drug concentration and bioavailability, enhanced the targeting of cancer cells, and has high clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004964715790000021
    Figure BDA0004964715790000021
  • Figure BDA0004964715790000031
    Figure BDA0004964715790000031
  • Figure BDA0004964715790000032
    Figure BDA0004964715790000032
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical compounds, and particularly discloses a glycosylated pyrazole curcumin derivative as well as a preparation method and application thereof. According to the glycosylated pyrazol curcumin derivative, pyrazol curcumin is used as a parent nucleus, a specific oligosaccharide group is introduced into a phenolic hydroxyl group of pyrazol curcumin, the obtained glycosylated pyrazol curcumin derivative has excellent activity of inhibiting lung cancer or hepatoma carcinoma cell proliferation in vitro, and the water solubility and the oil-water partition coefficient are remarkably improved compared with curcumin; the bioavailability is improved by improving the blood concentration and enhancing the targeting property of combining with cancer cells, and the compound can be used for preparing medicines for treating and preventing lung cancer or liver cancer. Meanwhile, the compound is rich in raw material source, low in price, simple in preparation process and convenient for industrial application. Therefore, the discovery of the compound is expected to provide a promising treatment scheme for patients with lung cancer or liver cancer, has important significance for breaking through the treatment bottleneck of lung cancer or liver cancer and developing curcumin into medicines, and has a wide potential application field.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of pharmaceutical compounds, and in particular to a glycosylated pyrazole curcumin derivative and a preparation method and application thereof. Background Art

[0002] Cancer is a malignant disease caused by the loss of normal regulation and excessive proliferation of body cells. It has become a major killer that endangers human life and health. Currently, cancer treatment is still a difficult task. Most of the chemotherapy drugs commonly used in clinical practice have disadvantages such as low efficacy on solid tumors, large toxic side effects, and easy to develop drug resistance. Therefore, the development of low-toxic and high-efficiency anti-tumor drugs is still one of the important research directions of today's medical research and development.

[0003] Curcumin (Cur) is a plant polyphenol extracted from the rhizome of the Chinese medicinal herb turmeric. It is included in the Pharmacopoeia of the People's Republic of China and is listed as a third-generation anticancer chemopreventive drug by the National Cancer Institute (NCI) of the United States. Curcumin alone or in combination with other clinical anticancer drugs shows a strong inhibitory effect on tumor cells, and has low toxicity to its own normal cells. Therefore, curcumin is expected to become a highly effective and low-toxic anticancer drug. However, the stability and poor water solubility caused by the structure of curcumin itself have greatly restricted the clinical application of curcumin. In order to solve the above problems, curcumin is used as a lead compound, and its structure is modified and transformed to improve the stability, water solubility and bioavailability of curcumin, which is of great significance to realize the clinical application value of curcumin. Summary of the invention

[0004] In view of the technical problems that curcumin is unstable under physiological conditions in vivo, has poor water solubility, and has low bioavailability when currently used clinically, the present invention provides a glycosylated pyrazole curcumin derivative, a preparation method, and an application thereof.

[0005] In order to solve the above technical problems, the technical solution provided by the present invention is:

[0006] In the first aspect, the present invention provides a glycosylated pyrazole curcumin derivative, the structure of which is shown in formula (I):

[0007]

[0008] Wherein, R2 is β-D-glucopyranosyl, β-D-galactopyranosyl, β-D-cellobiosyl or β-D-lactosyl.

[0009] Studies have confirmed that the diketone structure in the molecular structure of curcumin is the key factor that causes curcumin to be unstable under physiological conditions, and experiments have confirmed that its stability can be effectively improved by modifying the diketone structure.

[0010] Based on this, the inventors transformed the β-diketone structure of curcumin into an electron-rich five-membered pyrazole nitrogen heterocycle, and designed a new compound with pyrazole curcumin as the parent core and introduced a specific oligosaccharide group into its phenolic hydroxyl group. The water solubility of this compound is significantly better than that of curcumin, and the oil-water partition coefficient and drug stability are significantly improved. At the same time, it also has excellent anti-tumor activity, which provides new ideas for the development and utilization of new anti-tumor drugs and curcumin, and has high potential application value.

[0011] Specifically, the structural formula of R2 is shown below:

[0012]

[0013] Specifically, the structure of the glycosylated pyrazole curcumin derivative is as follows:

[0014]

[0015] Further preferably, the structure of the glycosylated pyrazole curcumin derivative is as follows:

[0016]

[0017] The present invention effectively increases the water solubility of the modified compound and improves the oil-water partition coefficient of the compound by structurally modifying the phenolic hydroxyl group of pyrazole curcumin, thereby facilitating the improvement of blood drug concentration and bioavailability. At the same time, the above-mentioned preferred compound has the targeting property of binding to cancer cells, can improve the killing property of tumor cells, and has a high clinical application value.

[0018] In a second aspect, the present invention also provides a method for preparing the above-mentioned glycosylated pyrazole curcumin derivatives, comprising the following steps:

[0019] Curcumin and hydrazine hydrate are used as raw materials, and pyrazole curcumin shown in formula (II) is obtained through cyclization reaction;

[0020] The pyrazole curcumin shown in formula (II) is protected by protecting the hydroxyl group to obtain the monohydroxy-protected pyrazole curcumin shown in formula (III);

[0021] The monohydroxy protected pyrazole curcumin represented by formula (III) and a saccharide compound are subjected to etherification reaction, and then deprotected to obtain a glycosylated pyrazole curcumin derivative represented by formula (I);

[0022]

[0023] Wherein, the carbohydrate compound is

[0024] Compared with the prior art, the preparation method of the glycosylated pyrazole curcumin derivatives provided by the present invention has short synthesis steps, simple operation, mild reaction conditions, high purity of the obtained product, good industrial utilization value, and high promotion and application value.

[0025] Furthermore, the preparation method of the glycosylated pyrazole curcumin derivatives specifically comprises the following steps:

[0026] S1, dissolving curcumin in glacial acetic acid, adding hydrazine hydrate, carrying out cyclization reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain pyrazole curcumin shown in formula (II);

[0027] S2, adding the pyrazole curcumin shown in formula (II) and an organic base into an organic solvent a, mixing evenly, adding TBS hydroxyl protective agent, and monitoring by thin layer chromatography until the reaction is completed to obtain a monohydroxyl protected pyrazole curcumin shown in formula (III);

[0028] S3, adding the monohydroxy protected pyrazole curcumin shown in formula (III), anhydrous potassium carbonate and tetrabutylammonium bromide to the organic solvent b, adding the sugar compound, carrying out etherification reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain the compound shown in formula (IV);

[0029]

[0030] wherein R1 is 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl, 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl, 2,3,6,2',3',4',6'-hepta-O-acetyl-β-D-cellobiosyl or 2,3,6,2',3',4',6'-hepta-O-acetyl-β-D-lactosyl;

[0031] S4, dissolving the compound represented by formula (IV) in an organic solvent c, adding glacial acetic acid, adding fluoride, carrying out a deprotection reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain an intermediate product;

[0032] S5, dissolving the intermediate product in an alcohol solvent, adding an alcohol solution of sodium methoxide until the pH of the system is weakly alkaline, carrying out a deprotection reaction, monitoring by thin layer chromatography until the reaction is completed, adjusting the pH to neutral, and obtaining a glycosylated pyrazole curcumin derivative represented by formula (I). The specific synthesis route is as follows:

[0033]

[0034] Specifically, the structural formula of R1 is as follows:

[0035]

[0036] Furthermore, the preparation method of the carbohydrate compound comprises the following steps:

[0037] The acetylating agent and the organic base are mixed evenly, the temperature is raised to 100°C to 120°C, the oligosaccharide compound is added, the temperature is kept for reaction, and thin layer chromatography is monitored until the reaction is completed, and the reaction liquid is cooled, and a mixed solution of hydrobromic acid and acetic acid is added dropwise to the reaction liquid at -5°C to 5°C. After the addition is completed, the reaction is carried out at 20°C to 30°C for 2h to 5h to obtain the sugar compound;

[0038] Wherein, the oligosaccharide compound is D-glucose, D-galactose, D-cellobiose or D-lactose.

[0039] Specifically, the structural formula of the above oligosaccharide compound is shown in Table 1:

[0040] Table 1 Structural formula of oligosaccharide compounds

[0041]

[0042] Furthermore, in combination with the above method for preparing sugar compounds, the acetylation agent is acetic anhydride or acetyl chloride, and the organic base is sodium acetate or pyridine.

[0043] Furthermore, in combination with the above method for preparing a carbohydrate compound, the molar ratio of the organic base, the acetylation agent and the oligosaccharide compound is (1-3):(5-15):1.

[0044] Furthermore, in combination with the above method for preparing sugar compounds, the mass content of hydrobromic acid in the mixed solution of hydrobromic acid and acetic acid is 30% to 35%.

[0045] Furthermore, in combination with the above-mentioned method for preparing a carbohydrate compound, after the reaction is completed, a post-treatment process is also included: pouring the reaction solution into ice water, extracting the aqueous phase with an organic solvent, washing the extract phase with purified water, a saturated sodium bicarbonate aqueous solution and saturated brine in sequence, drying over anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and recrystallizing with an alcohol solvent to obtain the carbohydrate compound.

[0046] In combination with the above method for preparing sugar compounds, as a specific embodiment of the present invention, the organic solvent is dichloromethane, ethyl acetate or diethyl ether; the alcohol solvent is methanol, ethanol or isopropanol.

[0047] Furthermore, in S1, the molar ratio of curcumin to hydrazine hydrate is 1:(1-10).

[0048] Furthermore, in S1, the molar volume ratio of curcumin to glacial acetic acid is 1 mmoL:(1-5) mL.

[0049] Furthermore, in S1, the temperature of the cyclization reaction is 90°C to 120°C.

[0050] Furthermore, after the reaction of S1 is completed, a post-treatment process is also included: the reaction solution is evaporated under reduced pressure to dry the solvent, the obtained crude product is dissolved in an organic solvent, and then washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate, filtered, the filtrate is concentrated under reduced pressure, and purified by pulping with an alcohol solvent to obtain the pyrazole curcumin shown in formula (II).

[0051] Specifically, in S1, during the post-treatment process, the organic solvent is dichloromethane, ethyl acetate or diethyl ether, and the alcohol solvent is methanol, ethanol or isopropanol.

[0052] Furthermore, in S2, the molar ratio of the organic base, the TBS hydroxyl protecting agent and the pyrazole curcumin represented by formula (II) is (1-4):(0.5-1.5):1.

[0053] Furthermore, in S2, the volume molar ratio of the organic solvent a to the pyrazole curcumin represented by formula (II) is (1-5) mL:1 mmoL.

[0054] Furthermore, in S2, the reaction temperature is 20°C to 40°C.

[0055] Furthermore, in S2, the organic solvent a is one or both of N,N-dimethylformamide (DMF) and dimethyl sulfoxide (DMSO).

[0056] Furthermore, in S2, the organic base is at least one of imidazole, pyridine or triethylamine.

[0057] Furthermore, in S2, the TBS hydroxyl protecting agent is tert-butyldimethylsilyl chloride (TBDMSCl) or tert-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf).

[0058] Furthermore, after the reaction S2 is completed, a post-treatment process is also included: adding water to the reaction solution for quenching, adding an organic solvent for extraction, then washing with a saturated sodium bicarbonate solution and a saturated saline solution in sequence, drying with anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain the monohydroxy protected pyrazole curcumin shown in formula (III).

[0059] Specifically, in S2, during the post-treatment process, the organic solvent is dichloromethane, ethyl acetate or diethyl ether.

[0060] Furthermore, in S3, the molar ratio of the anhydrous potassium carbonate, tetrabutylammonium bromide, sugar compound and the monohydroxy protected pyrazole curcumin represented by formula (III) is (8-30):(0.1-1):(0.8-3):1.

[0061] Furthermore, in S3, the organic solvent b is one or both of dichloromethane and acetone.

[0062] Furthermore, in S3, the volume molar ratio of the organic solvent b to the monohydroxy-protected pyrazole curcumin represented by formula (III) is (10-60) mL:1 mmoL.

[0063] Furthermore, in S3, the temperature of the etherification reaction is 20°C to 40°C.

[0064] Furthermore, after the completion of the S3 reaction, a post-treatment process is also included: adding water to the reaction solution for quenching, adding an organic solvent for extraction, and then washing with water, a saturated sodium bicarbonate solution and a saturated saline solution in sequence, drying over anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and performing silica gel column chromatography to obtain a compound represented by formula (IV).

[0065] Specifically, in S3, during the post-treatment process, the organic solvent is ethyl acetate, and the eluent for silica gel column chromatography is petroleum ether / ethyl acetate or dichloromethane / methanol.

[0066] Furthermore, in S4, the volume molar ratio of the glacial acetic acid, the fluoride and the compound represented by formula (IV) is (0.02-0.2) mL:(0.5-2) mL:1 mmoL.

[0067] Furthermore, in S4, the organic solvent c is anhydrous tetrahydrofuran.

[0068] Furthermore, in S4, the fluoride is tetrabutylammonium fluoride or pyridine hydrogen fluoride complex.

[0069] Furthermore, in S4, the volume molar ratio of the organic solvent c to the compound represented by formula (IV) is (5-20) mL:1 mmoL.

[0070] Furthermore, in S4, the temperature of the deprotection reaction is -10°C to 10°C.

[0071] Furthermore, after the S4 reaction is completed, a post-treatment process is also included: adding water to the reaction solution for quenching, adding an organic solvent for extraction, and then washing with water, a saturated sodium bicarbonate solution and a saturated saline solution in sequence, drying over anhydrous sodium sulfate, filtering, and concentrating the filtrate under reduced pressure to obtain an intermediate product.

[0072] Specifically, in the post-treatment process in S4, the organic solvent is ethyl acetate.

[0073] Furthermore, in S5, the alcohol solvent is at least one of methanol, ethanol or isopropanol.

[0074] Furthermore, in S5, the volume molar ratio of the alcohol solvent to the intermediate product is (10-40) mL:1 mmoL.

[0075] Furthermore, in S5, the weak alkalinity refers to a pH of 9 to 10.

[0076] Furthermore, after the reaction S5 is completed, a post-treatment process is also included: the reaction solution is filtered, the filtrate is concentrated under reduced pressure, and the obtained crude product is recrystallized with an alcohol solvent to obtain a glycosylated pyrazole curcumin derivative represented by formula (I).

[0077] Specifically, in the post-treatment process in S5, the alcohol solvent is methanol, ethanol or isopropanol.

[0078] The above-mentioned preferred reaction conditions are conducive to improving the yield and purity of the products in each step.

[0079] The present invention also provides the use of the glycosylated pyrazole curcumin derivatives in the preparation of anti-liver cancer or lung cancer drugs.

[0080] The glycosylated pyrazole curcumin derivatives provided by the present invention have excellent in vitro activity of inhibiting the proliferation of lung cancer or liver cancer cells, and the water solubility and oil-water partition coefficient are significantly improved relative to curcumin, which is conducive to improving blood drug concentration and enhancing the targeting of binding to cancer cells to improve its bioavailability, and can be used to prepare drugs for treating and preventing lung cancer or liver cancer. At the same time, the raw material source of the compound is abundant, the price is low, the preparation process is simple, and it is easy to industrialize. Therefore, the discovery of the compound is expected to provide a very promising treatment plan for patients with lung cancer or liver cancer, which is of great significance for breaking through the treatment bottleneck of lung cancer or liver cancer and the development of curcumin into medicine, and has a broad potential application field. DETAILED DESCRIPTION

[0081] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0082] The embodiment of the present invention provides a method for preparing a glycosylated pyrazole curcumin derivative, comprising the following steps:

[0083] Curcumin (Formula 1) and hydrazine hydrate are used as raw materials, and a cyclization reaction is performed to obtain pyrazole curcumin shown in Formula 2;

[0084] After the hydroxyl group of the pyrazole curcumin shown in Formula 2 is protected, the monohydroxy-protected pyrazole curcumin shown in Formula 3 is obtained;

[0085] The monohydroxy protected pyrazole curcumin shown in Formula 3 and the saccharide compounds (Formulas 4 to 7) are subjected to etherification reaction to obtain compounds shown in Formulas 8 to 11;

[0086] The compounds represented by Formula 8 to Formula 11 are sequentially deprotected from hydroxyl groups and acetyl groups to obtain glycosylated pyrazole curcumin derivatives represented by Formula 12 to Formula 15. The specific reaction route is as follows:

[0087]

[0088] In order to better illustrate the present invention, further examples are given below.

[0089] Example 1

[0090] Synthesis of the compound represented by formula 2

[0091] At room temperature, hydrazine hydrate (2.80 g, 55.81 mmol) was slowly dripped into a solution of curcumin (10.00 g, 27.10 mmol) in glacial acetic acid (100 mL). After the addition was completed, the mixture was stirred and heated to 110 ° C. During the reaction, the reaction solution changed from an orange-yellow suspension to a reddish brown clarification. The reaction progress was monitored by TLC thin-layer chromatography. The reaction was stopped after 8 h. The solvent was evaporated to dryness, and the crude product was dissolved in 50 mL of ethyl acetate. The organic phase was washed with water (15 mL) and saturated brine (15 mL) in turn. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. Anhydrous ethanol (20 mL) was added for pulping and purification, filtered, and the filter cake was dried to obtain the compound shown in formula 2 as a light yellow solid, 5.50 g, and the yield was 55.0%.

[0092] Structural Elucidation Data:

[0093] Melting point: (212.7-215.1)℃.

[0094] 1 H NMR (500MHz, DMSO-d6): δ12.78(s,1H),9.16(s,2H),7.14(s,2H),7.04(m,2H),6.94–6.90(m,4H),6.77(m,2H),6.58(s,1H),3.83(s,6H).

[0095] LC-MS(ESI,m / z)Calcd for:C 21 H 21 N2O4[M+H + ]:365.1,found:365.1.

[0096] Example 2

[0097] Synthesis of the compound represented by formula 3

[0098] At room temperature, the compound of formula 2 (1.50 g, 4.12 mmol) and imidazole (0.31 g, 4.53 mmol) were added to 8 mL of N,N-dimethylformamide (DMF). After the addition was completed, TBDMSCl (0.50 g, 3.29 mmol) was added after stirring for 30 min. The reaction progress was monitored by TLC thin-layer chromatography. After reacting at room temperature for 4 h, 10 mL of water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×30 mL). The organic phases were combined and washed with pure water (30 mL), saturated sodium bicarbonate aqueous solution (30 mL) and saturated brine (30 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was chromatographed on a silica gel column (eluent: petroleum ether: ethyl acetate = 1.5:1 to 1:1, v / v) to obtain the compound of formula 3 as a white solid powder 0.70 g with a yield of 40.2%.

[0099] Structural Elucidation Data:

[0100] Melting point: (141.2-144.5)℃.

[0101] 1 H NMR (500MHz, DMSO-d6): δ12.86(s,1H),9.16(s,1H),7.21(s,1H),7.16(s,1H),7.07–7.00(m,4H), 6.96–6.94(m,2H),6.82(m,2H),6.66(s,1H),3.85(s,3H),3.85(s,3H),0.98(s,9H),0.16(s,6H).

[0102] LC-MS(ESI,m / z)Calcd for:C 27 H 35 N2O4Si[M+H] + :479.2,found:479.3.

[0103] Example 3

[0104] Synthesis of carbohydrate compounds represented by formula 4 to formula 7

[0105] Synthesis of the compound represented by formula 4

[0106] At room temperature, add anhydrous sodium acetate (0.46 g, 5.55 mmol) into a 100 mL flask, add 5.37 mL of acetic anhydride (Ac2O), stir and heat to 110 ° C, add D-glucose (1.00 g, 5.55 mmol) in batches after 20 minutes, and continue stirring for 2 hours after all the solids are dissolved. After the reaction is complete as monitored by TLC thin-layer chromatography, stop heating and cool the reaction solution to room temperature. At 0°C, 2.50 mL of 33% HBr / AcOH solution was added dropwise to the reaction solution. After the addition was complete, the temperature was raised to room temperature and the reaction was stirred for 3 h. The reaction solution was poured into ice water (120 mL), and the aqueous phase was extracted with dichloromethane (60 mL). The organic phase was washed with pure water (30 mL), saturated sodium bicarbonate aqueous solution (30 mL) and saturated brine (30 mL) in sequence. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and recrystallized with ethanol to obtain the compound shown in Formula 4 as a white solid powder (1.86 g) with a yield of 80.3%.

[0107] Structural Elucidation Data:

[0108] Melting point: (88.5-90.2)℃.

[0109] 1 H NMR (500MHz, CDCl3): δ6.64(d,J=4.0Hz,1H),5.59(t,J=9.7Hz,1H),5.19(t,J=9.7Hz,1H),4.87(dd,J= 10.0,4.0Hz,1H),4.38–4.31(m,2H),4.16(m,1H),2.13(s,3H),2.12(s,3H),2.08(s,3H),2.07(s,3H).

[0110] Synthesis of the compound represented by formula 5

[0111] The feed amount and reaction steps are the same as those of the compound shown in Formula 4, except that D-glucose is replaced by an equal molar amount of D-galactose, which will not be repeated here. The compound shown in Formula 5 is obtained as a white solid powder of 1.80 g, with a yield of 79.8%.

[0112] Structural Elucidation Data:

[0113] Melting point: (84.3-85.6)℃.

[0114] 1H NMR (500MHz, CDCl3): δ6.73(d,J=4.0Hz,1H),5.55(m,1H),5.44(dd,J=10.5,3.3Hz,1H),5.08(dd,J=10.5,3.3Hz,1H),4.52(t, J=6.5Hz,1H),4.22(dd,J=11.5,6.4Hz,1H),4.14(dd,J=11.5,6.7Hz,1H),2.18(s,3H),2.15(s,3H),2.09(s,3H),2.04(s,3H).

[0115] Synthesis of the compound represented by formula 6

[0116] At room temperature, add anhydrous sodium acetate (0.42 g, 5.55 mmol) into a 100 mL flask, add 5.80 mL acetic anhydride (Ac2O), stir and heat to 110 ° C. After reacting for 20 minutes, add cellobiose (1.88 g, 5.55 mmol) in batches. After all the solids are dissolved, continue stirring for 2 hours. After the reaction is complete as monitored by TLC thin-layer chromatography, stop heating and cool the reaction solution to room temperature. At 0°C, 2.50 mL of 33% HBr / AcOH solution was added dropwise to the reaction solution. After the addition was complete, the temperature was raised to room temperature and the reaction was stirred for 3 h. The reaction solution was poured into ice water (120 mL), and the aqueous phase was extracted with dichloromethane (60 mL). The organic phase was washed with pure water (30 mL), saturated sodium bicarbonate aqueous solution (30 mL) and saturated brine (30 mL) in sequence. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure and recrystallized with ethanol to obtain the compound shown in Formula 6 as a white solid powder (1.78 g) with a yield of 87.5%.

[0117] Structural Elucidation Data:

[0118] 1 H NMR (500MHz, CDCl3): δ6.53(d,J=4.0Hz,1H),5.53(t,J=9.5Hz,1H),5.15(t,J=9.5Hz,1H),5.08(m,1H),4.94(t,J=9.5Hz,1H),4.77(t,J=9 .5Hz,1H),4.55(d,J=8.0Hz,1H),4.53(m,1H),4.37(m,1H),4.20-4.18(m,2H),4.06(m,1H),3.84(m,1H),3.68(m,1H),2.26–1.96(m,21H).

[0119] Synthesis of the compound represented by formula 7

[0120] The feed amount and reaction steps are the same as those of the compound shown in Formula 6, except that D-cellobiose is replaced by an equal amount of D-lactose, which will not be described again. The compound shown in Formula 7 is obtained as a white solid powder of 1.80 g, with a yield of 88.1%.

[0121] Structural Elucidation Data:

[0122] 1 H NMR (500MHz, CDCl3): δ6.56(d,J=4.0Hz,1H),5.59(t,J=9.5Hz,1H),5.39(d,J=3.1Hz,1H),5.18–5.14(m,1H),5.00(dd,J=1 0.4,3.4Hz,1H),4.79(dd,J=10.0,4.0Hz,1H),4.56–4.52(m,2H),4.23–4.11(m,4H),3.90-3.94(m,2H),2.19-2.00(m,21H).

[0123] Example 4

[0124] Synthesis of compounds represented by formula 8 to formula 11

[0125] Compound represented by formula 8: R1 = 2,3,4,6-tetra-O-acetyl-β-D-pyranose;

[0126] Compound represented by formula 9: R1 = 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl;

[0127] Compound represented by formula 10: R1 = 2,3,6,2',3',4',6'-hepta-O-acetyl-β-D-cellobiosyl;

[0128] The compound represented by formula 11: R1 = 2,3,6,2',3',4',6'-hepta-O-acetyl-β-D-lactosyl.

[0129] Synthesis of the compound represented by formula 8

[0130] At room temperature, weigh the compound shown in formula 3 (0.10 g, 0.20 mmol) in a 50 mL flask, add anhydrous K2CO3 (0.28 g, 2.00 mmol) and tetrabutylammonium bromide (TBAB) (0.02 g, 0.06 mmol), add 8 mL of dichloromethane, stir and dissolve at room temperature, add 2 mL of dichloromethane solution of the compound shown in formula 4 (0.10 g, 0.24 mmol) dropwise into the above reaction solution, after the addition is complete, continue to stir and react for 24 hours, After the reaction was completed as monitored by TLC thin-layer chromatography, water was added to quench the reaction, and the mixture was extracted with ethyl acetate (3×15 mL). The organic phases were combined and washed with pure water (15 mL), saturated sodium bicarbonate aqueous solution (15 mL) and saturated brine (15 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The filtrate was chromatographed on a silica gel column (eluent: dichloromethane: methanol = 80:1-60:1, v / v) to obtain the compound shown in Formula 8 as a light yellow viscous liquid (0.04 g) with a yield of 30.1%.

[0131] Structural Elucidation Data:

[0132] 1 H NMR (500MHz, DMSO-d6): δ12.95(s,1H),7.20–7.00(m,9H),6.85(s,1H),6.70(s,1H),5.41(t,J=9.6Hz,2H),5.08(dd,J=9.7,8.1Hz,1H),5.02(t,J= 9.6Hz,1H),4.26–4.19(m,2H),4.10(d,J=10.3Hz,1H),3.85(s,3H),3.84 (s,3H),2.05(m,6H),2.03(s,3H),1.99(s,3H),0.98(s,9H),0.16(s,6H).

[0133] LC-MS(ESI,m / z)Calcd for:C 41 H 53 N2O 13 Si[M+H] + :809.3,found:809.4.

[0134] Synthesis of the compound represented by formula 9

[0135] The feed amount and reaction steps are the same as those of the compound shown in Formula 8, except that the compound shown in Formula 4 is replaced by an equal amount of the compound shown in Formula 5, to obtain the compound shown in Formula 9, which is a brown viscous liquid of 0.26 g, with a yield of 31.6%.

[0136] Structural Elucidation Data:

[0137] 1 H NMR (500MHz, Methanol-d4): δ7.18(d,J=1.5Hz,1H),7.15–7.13(m,3H),7.11(d,J=3.5Hz,1H),7.07(dd,J= 8.4,1.6Hz,1H),7.03–7.00(m,2H),6.98(d,J=10.9Hz,1H),6.84(d,J=8.1Hz,1H),6.69(s,1H),5.46(s,1H) ,5.44(m,1H),5.41(dd,J=10.4,8.0Hz,1H),5.25(dd,J=10.5,3.5Hz,1H),5.11(d,J=7.9Hz,1H),4.20(m,2H ),4.12(m,1H),3.87(s,6H),2.19(s,3H),2.10(s,3H),2.03(s,3H),2.00(s,3H),1.03(s,9H),0.19(s,6H).

[0138] LC-MS(ESI,m / z)Calcd for:C 41 H 53 N2O 13 Si[M+H] + :809.3,found:809.4.

[0139] Synthesis of the compound represented by formula 10

[0140] The compound shown in formula 3 (0.56 g, 1.18 mmol) was weighed into a 100 mL flask, anhydrous K2CO3 (2.93 g, 21.19 mmol) and TBAB (0.23 g, 0.76 mmol) were added, and 8 mL of dichloromethane was added. The mixture was stirred and dissolved at room temperature. 10 mL of dichloromethane solution of the compound shown in formula 6 (0.82 g, 1.18 mmol) was added dropwise to the above reaction solution. After the addition was completed, the reaction was continued under stirring for 24 h. TLC After the reaction was completed by thin layer chromatography monitoring, it was extracted with ethyl acetate (3×10 mL), the organic phases were combined, washed with pure water (15 mL), saturated sodium bicarbonate aqueous solution (15 mL) and saturated brine (15 mL) in sequence, the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. After silica gel column chromatography (eluent: dichloromethane: methanol = 80:1 to 60:1, v / v), the compound shown in formula 10 was obtained as a light yellow viscous liquid 0.26 g, and the yield was 25.1%.

[0141] Structural Elucidation Data:

[0142] 1H NMR (500MHz, Methanol-d4): δ7.21(d,J=1.7Hz,1H),7.17–7.15(m,2H),7.14–7.12(m,2H),7.08(dd,J=8.4,1.8Hz,1H),7.05–7.03(m ,2H),6.99(d,J=10.6Hz,1H),6.86(d,J=8.1Hz,1H),6.72(s,1H),5.52(s,1H),5.34–5.25(m,3H),5.18–5.15(m,2H),5.07–5.03(m,2H ),4.78(d,J=8.0Hz,1H),4.59–4.56(m,1H),4.45(dd,J=12.5,4.1Hz,1H),4.25(dd,J=11.9,6.1Hz,1H),4.14–4.12(m,1H),4.10(m,1 H),3.98–3.96(m,1H),3.89(s,6H),2.14(s,3H),2.10–2.09(m,9H),2.07(s,3H),2.03(s,3H),1.98(s,3H),1.04(s,9H),0.20(s,6H).

[0143] HRMS(ESI,m / z)Calcd for:C 53 H 69 N2O 21 Si[M+H] + :1097.4162,found:1097.4156.

[0144] Synthesis of the compound represented by formula 11

[0145] The feed amount and reaction steps are the same as those of the compound shown in Formula 10, except that the compound shown in Formula 6 is replaced by an equal molar amount of the compound shown in Formula 7, to obtain the compound shown in Formula 11, which is a light yellow viscous liquid of 0.21 g, with a yield of 20.1%.

[0146] Structural Elucidation Data:

[0147] 1H NMR (500MHz, CDCl3): δ7.07–7.06(m,3H),7.04–7.03(m,2H),7.02–6.99(m,3H),6.95–6.93(m,1H),6.86(d,J=8.1Hz,1H ),6.64(s,1H),5.39(m,1H),5.32(t,J=9.1Hz,1H),5.25–5.21(m,1H),5.16(dd,J=10.4,7.8Hz,1H),5.02–4.98(m,2H), 4.57–4.54(m,2H),4.20(d,J=5.5Hz,1H),4.17(d,J=6.1Hz,1H),4.15–4.11(m,2H),3.93–3.92(m,2H),3.87(s,6H),3.7 7-3.73(m,1H),2.19(s,3H),2.14(s,3H),2.12(s,6H),2.10(s,3H),2.08(s,3H),2.00(s,3H),1.04(s,9H),0.20(s,6H).

[0148] HRMS(ESI,m / z)Calcd for:C 53 H 69 N2O 21 Si[M+H] + :1097.4162,found:1097.4156.

[0149] Example 5

[0150] Synthesis of glycosylated pyrazole curcumin derivatives represented by formula 12 to formula 15

[0151] The structural formula of the glycosylated pyrazole curcumin derivatives prepared in this example is shown in Table 2 below:

[0152] Table 2 Structural formula of target compounds

[0153]

[0154]

[0155] Synthesis of the compound represented by formula 12

[0156] At room temperature, the compound shown in formula 8 (0.34 g, 0.43 mmol) was added to a 25 mL flask, and 5 mL of anhydrous tetrahydrofuran and 0.03 mL of glacial acetic acid were added. 0.47 mL of tetrabutylammonium fluoride was added dropwise in an ice-water bath. After the addition was completed, the reaction was kept in an ice bath for 30 min. After the reaction was completed by TLC thin-layer chromatography, water was added to quench the reaction, and the reaction was extracted with ethyl acetate (3×10 mL). The organic phases were combined and washed with water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence. The organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was directly used in the next step.

[0157] The crude product was added to a 50 mL flask, and 10 mL of methanol was added. Under stirring at room temperature, 1 mol / L sodium methoxide methanol solution was added dropwise to adjust the pH to 9-10. The reaction was continued for 20 min. After the reaction was completed, H + The pH of the exchange resin was adjusted to neutral, filtered, and the filtrate was concentrated under reduced pressure. The crude product was recrystallized from isopropanol to obtain the compound of formula 12 as a light yellow solid powder (0.26 g) with a yield of 39.8%.

[0158] Structural Elucidation Data:

[0159] Melting point: (132.1-134.6)℃.

[0160] 1 H NMR (500MHz, Methanol-d4): δ7.22(s,1H),7.19(d,J=8.4Hz,1H),7.15(s,1H),7 .13–7.11(m,2H),7.10(s,1H),7.02–7.00(m,2H),6.92(d,J=16.4Hz,1H),6.82(d ,J=8.1Hz,1H),6.69(s,1H),4.96(d,J=7.5Hz,1H),3.94(s,3H),3.95(s,3H),3. 92–3.91(m,1H),3.74(m,1H),3.55–3.53(m,1H),3.50(m,1H),3.47–3.44(m,2H).

[0161] LC-MS(ESI,m / z)Calcd for:C 27 H 31 N2O9[M+H] + :527.20,found:527.30.

[0162] Synthesis of the compound represented by formula 13

[0163] At room temperature, the compound shown in formula 9 (0.23 g, 0.29 mmol) was added to a 25 mL flask, and 5 mL of anhydrous tetrahydrofuran and 0.02 mL of glacial acetic acid were added. 0.30 mL of tetrabutylammonium fluoride was added dropwise in an ice-water bath. After the addition was completed, the reaction was kept in an ice bath for 30 min. After the reaction was completed by TLC thin-layer chromatography, water was added to quench the reaction, and the reaction was extracted with ethyl acetate (3×10 mL). The organic phases were combined, washed with water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence, and the organic phases were collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain a crude product, which was directly used in the next step.

[0164] The crude product was added to a 50 mL flask, and then added to 10 mL of methanol. Under stirring at room temperature, 1 mol / L sodium methoxide methanol solution was added dropwise to adjust the pH to 9-10. The reaction was continued for 20 min. After the reaction was completed, H + The pH of the exchange resin was adjusted to neutral, filtered, and the filtrate was concentrated under reduced pressure. The crude product was recrystallized from isopropanol to obtain the compound of formula 13 as a light yellow solid powder (0.06 g) with a yield of 40.8%.

[0165] Structural Elucidation Data:

[0166] Melting point: (179.2-181.2)℃.

[0167] 1 H NMR (500MHz, DMSO-d6): δ12.85(s,1H),9.18(s,1H),7.22(s,1H),7.16(s,1H),7.12–7. 08(m,2H),7.05–7.02(m,3H),6.96–6.93(m,2H),6.79(d,J=8.1Hz,1H),6.66(s,1H),5. 08(d,J=5.1Hz,1H),4.92(d,J=7.7Hz,1H),4.85(d,J=4.6Hz,1H),4.65–4.64(m,1H),4. 51(m,1H),3.85(s,3H),3.85(s,3H),3.73(s,1H),3.62–3.56(m,3H),3.49-3.44(m,2H).

[0168] LC-MS(ESI,m / z)Calcd for:C 27 H 31 N2O9[M+H] + :527.20,found:527.10.

[0169] Synthesis of the compound represented by formula 14

[0170] At room temperature, weigh the compound shown in formula 10 (0.16 g, 0.16 mmol), add 3 mL of anhydrous tetrahydrofuran and 0.01 mL of glacial acetic acid, add 0.17 mL of tetrabutylammonium fluoride dropwise in an ice-water bath, after the addition is complete, keep in an ice bath for 30 min, after the reaction is completed by TLC thin-layer chromatography, add water to quench, extract with ethyl acetate (3×10 mL), combine the organic phases, wash with water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence, collect the organic phases, add an appropriate amount of anhydrous sodium sulfate to dry the organic phases, filter, and concentrate the filtrate under reduced pressure to obtain a crude product, which is directly used in the next step reaction.

[0171] The crude product was added to a 50 mL flask and dissolved in 5 mL methanol. Under stirring at room temperature, 1 mol / L sodium methoxide methanol solution was added dropwise to adjust the pH to 9-10. The reaction was continued for 20 min. After the reaction was completed, H + The pH of the exchange resin was adjusted to neutral, filtered, and the filtrate was concentrated under reduced pressure. The crude product was recrystallized from isopropanol to obtain the compound of formula 14 as a white solid powder (0.04 g) with a yield of 37.7%.

[0172] Structural Elucidation Data:

[0173] Melting point: (180.2-181.7)℃.

[0174] 1 H NMR (500MHz, Methanol-d4): δ7.16–7.12(m,6H),7.03–7.02(m,2H),6.92(m,1H),6.83(m,1H) ,6.72(s,1H),5.01(d,J=6.5Hz,1H),4.49(d,J=6.5Hz,1H),3.94(s,12H),3.72–3.62(m,6H).

[0175] HRMS(ESI,m / z)Calcd for:C 33 H 41 N2O 14 [M+H] + :689.2558,found:689.2560.

[0176] Synthesis of the compound represented by formula 15

[0177] At room temperature, weigh the compound shown in formula 11 (0.10 g, 0.09 mmol), add 1.6 mL of anhydrous tetrahydrofuran and 0.01 mL of glacial acetic acid, add 0.10 mL of tetrabutylammonium fluoride dropwise in an ice-water bath, after the addition is complete, keep in an ice bath for 30 min, after the reaction is completed by TLC thin-layer chromatography, add water to quench, extract with ethyl acetate (3×10 mL), combine the organic phases, wash with water (10 mL), saturated sodium bicarbonate aqueous solution (10 mL) and saturated brine (10 mL) in sequence, collect the organic phases, add an appropriate amount of anhydrous sodium sulfate to dry, filter, and concentrate the filtrate under reduced pressure to obtain a crude product, which is directly used in the next step reaction.

[0178] The crude product was added to a 50 mL flask and dissolved in 3 mL methanol. Under stirring at room temperature, 1 mol / L sodium methoxide methanol solution was added dropwise to adjust the pH to 9-10. The reaction was continued for 20 min. After the reaction was completed, H + The pH of the exchange resin was adjusted to neutral, filtered, and the filtrate was concentrated under reduced pressure. The crude product was recrystallized from isopropanol to obtain the compound of formula 15 as a white solid powder (0.04 g) with a yield of 66.5%.

[0179] Structural Elucidation Data:

[0180] Melting point: (190.5-191.5)℃.

[0181] 1 H NMR (500MHz, DMSO-d6): δ7.23(d,J=1.5Hz,1H),7.17(d,J=1.5Hz,1H),7.10–7.09(m,2H),7.06–7.03(m,3H),6.96–6.93(m,2H),6.79(d,J =8.1Hz,1H),6.68(s,1H),5.05(d,J=7.8Hz,1H),4.27(d,J=7.1Hz,1H),3.86(s,3H),3.85(s,3H),3.67–3.64(m,4H),3.58–3.33(m,17H).

[0182] HRMS(ESI,m / z)Calcd for:C 33 H 41 N2O 14 [M+H] + :689.2558,found:689.2560.

[0183] The reaction raw materials in the above embodiments, as well as the parameters such as the amount of each reaction raw material added, reaction temperature and time can adopt other reaction conditions specified in the present invention. As long as they are within the range specified in the present invention, compounds of Formulas 12 to 15 with higher purity can be prepared.

[0184] Example 6

[0185] Physicochemical properties of target compounds

[0186] 1. Solubility test

[0187] (1) HPLC chromatographic conditions

[0188] Chromatographic column: Thermo Fisher 5TC-C18, 250 mm × 4.6 mm, 5 μm;

[0189] Detection wavelength: 330nm;

[0190] Mobile phase: 70% methanol: 30% water;

[0191] Injection volume: 20 μL;

[0192] Flow rate: 1mL / min.

[0193] (2) Drawing of standard curve

[0194] Accurately weigh 5.0 mg of each of curcumin and the target compound (compounds shown in Formula 12 to Formula 15) prepared in Example 5, put them into a 5 mL volumetric flask, add methanol to dissolve them, shake well, and adjust the volume to obtain a 1.0 mg / mL stock solution. The stock solution was diluted step by step to obtain standard solutions with concentrations of 50 μg / mL, 25 μg / mL, 12.5 μg / mL, 6.25 μg / mL, and 3.125 μg / mL, respectively. Each standard solution was filtered through a 0.22 μm microporous filter membrane and then sampled and tested, and the peak area was recorded. The peak area was used for linear regression analysis of the sample concentration to obtain a standard curve, as shown in Table 3. The linear range of the curve is 3.125 μg / mL to 50 μg / mL.

[0195] Table 3 Standard curve

[0196]

[0197] (3) Solubility determination

[0198] Each target compound and curcumin were weighed and dissolved in 1 mL of distilled water and phosphate buffer with pH values ​​of 3.3, 5.8 and 7.4, respectively. After shaking in a constant temperature oscillator at 37 °C for 48 h, the mixture was centrifuged at 10,000 r / min for 8 min. The supernatant was taken and filtered through a 0.22 μm microporous membrane before injection. The peak area Y was recorded and substituted into the regression equation to calculate the solubility. The results are shown in Table 4.

[0199] Table 4 Solubility of compounds represented by formula 12 to formula 15 in water and phosphate buffered saline solutions of different pH values

[0200]

[0201] As can be seen from the table, the solubility of the compounds represented by Formula 12 to Formula 15 in water is about 100 to 300 times higher than the solubility of curcumin in water reported in the literature (11 ng / mL). The solubility of the compounds represented by Formula 12 to Formula 15 in various phosphate buffers is also significantly higher than that of curcumin, especially the disaccharide-modified compounds represented by Formula 14 and Formula 15, whose solubility is increased by about 30,000 times. It can be seen that the water solubility of the synthesized compounds is greatly improved compared with curcumin.

[0202] 2. Determination of oil-water partition coefficient

[0203] Take 4 portions of 1 mL of 1.0 mg / mL water-saturated n-octanol solution of the compounds represented by Formula 12 to Formula 15, of which 1 mL of phosphate buffered saline with pH values ​​of 3.3, 5.8 and 7.4 is added to the first three portions of each compound, and 1 mL of saturated n-octanol aqueous solution is added to the fourth portion. Each mixed solution is placed in a 37°C constant temperature oscillator and shaken for 48 hours, and then centrifuged at 10000 r / min for 8 minutes. The aqueous phase concentration is detected by HPLC, and the peak area is recorded and substituted into the standard curve equation to obtain C W , calculate P app , the results are shown in Table 5.

[0204] P app =(C0-C W ) / C W

[0205] Where P app : apparent oil-water partition coefficient;

[0206] C0: concentration of target compound in water-saturated n-octanol;

[0207] C W : The concentration of the target compound in water or phosphate buffer solution saturated with n-octanol;

[0208] Table 5 Oil-water partition coefficients of compounds represented by formula 12 to formula 15 in water and buffer solutions of different pH values

[0209]

[0210] The oil-water partition coefficient of a drug affects the drug uptake by the human body. The oil-water partition coefficient log P app <-1 or logP app >5 is not conducive to the absorption of drugs by the human body, and the bioavailability of drugs is low. According to the solubility of curcumin in water of 11ng / mL, its log P app The log P value of the synthesized target compound is about 6, indicating that curcumin has strong lipophilicity and is not conducive to its absorption in the body. app Most of the values ​​were between 0 and 3, which were within the ideal range, indicating that it might have good bioavailability.

[0211] Example 7

[0212] In vitro antitumor activity test

[0213] The CCK-8 method was used to determine the proliferation inhibitory activity of the target compounds (compounds represented by Formula 12 to Formula 15) on human liver cancer cell HepG2 and human non-small cell lung cancer cell A549.

[0214] 1. Biological activity test

[0215] Human liver cancer cells HepG2 and human non-small cell lung cancer cells A549 that were frozen in the logarithmic growth period were placed in a 37°C water bath and shaken to thaw. After the cancer cells were revived, they were pipetted into a centrifuge tube with a 3 mL pipette and centrifuged. The supernatant was added to 1 mL of MEM medium (containing NEAA). HepG2 cells and A549 cells were cultured at a rate of 1 × 10 5 / well was inoculated into a 96-well plate and placed in a constant temperature incubator (5% CO2, 37°C) for overnight culture. The original culture medium was removed and different concentrations (0 μM / L, 0.001 μM / L, 0.01 μM / L, 0.1 μM / L, 1 μM / L, 4 μM / L, 8 μM / L, 16 μM / L, 32 μM / L, 64 μM / L, 128 μM / L) of the target compound, curcumin and positive control drug doxorubicin were added. The 96-well plate after drug addition was placed in a constant temperature incubator for culture for 24 h, and then CCK-8 reagent (10 μL per well) was added. The 96-well plate was continued to be incubated in the incubator for 4 h. After the incubation, the absorbance OD was measured at 450 nm using a microplate reader.

[0216] The cell inhibition rate was calculated by the following formula:

[0217] Cell inhibition rate (%) = 1-(OD treatment / OD blank control) × 100%, anti-tumor data analysis was performed using GraphPad Prism software to calculate the cell half inhibitory concentration (IC 50 ). The results are shown in Table 6.

[0218] Table 6 IC of compounds represented by formula 12 to formula 15 on human tumor cells 50 value

[0219]

[0220]

[0221] As can be seen from the above table, compared with curcumin, the compound shown in formula 12 has a stronger inhibitory effect on A549 and HepG2 cells, and the compound shown in formula 13 has a stronger inhibitory effect on HepG2 cells than curcumin itself. The disaccharide-modified derivative compound shown in formula 14 exhibits an anticancer activity comparable to that of curcumin, while the anticancer activity of the compound shown in formula 15 is weaker.

[0222] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A glycosylated pyrazole curcumin derivative, characterized in that: Its structure is shown in formula (I): Wherein, R2 is β-D-glucopyranosyl, β-D-galactopyranosyl, β-D-cellobiosyl or β-D-lactosyl.

2. The glycosylated pyrazole curcumin derivative according to claim 1, characterized in that: The structure of the glycosylated pyrazole curcumin derivative is shown below:

3. A method for preparing a glycosylated pyrazole curcumin derivative according to claim 1 or 2, characterized in that: The steps include: Curcumin and hydrazine hydrate are used as raw materials, and pyrazole curcumin shown in formula (II) is obtained through cyclization reaction; The pyrazole curcumin shown in formula (II) is protected by protecting the hydroxyl group to obtain the monohydroxy-protected pyrazole curcumin shown in formula (III); The monohydroxy protected pyrazole curcumin represented by formula (III) and a saccharide compound are subjected to etherification reaction, and then deprotected to obtain a glycosylated pyrazole curcumin derivative represented by formula (I); Wherein, the carbohydrate compound is 4. The method for preparing the glycosylated pyrazole curcumin derivatives according to claim 3, characterized in that: The specific steps include: S1, dissolving curcumin in glacial acetic acid, adding hydrazine hydrate, carrying out cyclization reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain pyrazole curcumin shown in formula (II); S2, adding the pyrazole curcumin shown in formula (II) and an organic base into an organic solvent a, mixing evenly, adding TBS hydroxyl protective agent, and monitoring by thin layer chromatography until the reaction is completed to obtain a monohydroxyl protected pyrazole curcumin shown in formula (III); S3, adding the monohydroxy protected pyrazole curcumin shown in formula (III), anhydrous potassium carbonate and tetrabutylammonium bromide to the organic solvent b, adding the sugar compound, carrying out etherification reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain the compound shown in formula (IV); wherein R1 is 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl, 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl, 2,3,6,2',3',4',6'-hepta-O-acetyl-β-D-cellobiosyl or 2,3,6,2',3',4',6'-hepta-O-acetyl-β-D-lactosyl; S4, dissolving the compound represented by formula (IV) in an organic solvent c, adding glacial acetic acid, adding fluoride, carrying out a deprotection reaction, and monitoring by thin layer chromatography until the reaction is completed to obtain an intermediate product; S5, dissolving the intermediate product in an alcohol solvent, adding an alcohol solution of sodium methoxide until the pH of the system is weakly alkaline, carrying out a deprotection reaction, monitoring by thin layer chromatography until the reaction is completed, adjusting the pH to neutral, and obtaining a glycosylated pyrazole curcumin derivative represented by formula (I).

5. The method for preparing the glycosylated pyrazole curcumin derivatives according to claim 3 or 4, characterized in that: The preparation method of the carbohydrate compound comprises the following steps: The acetylating agent and the organic base are mixed evenly, the temperature is raised to 100°C to 120°C, the oligosaccharide compound is added, the temperature is kept for reaction, and thin layer chromatography is monitored until the reaction is completed, and the reaction liquid is cooled, and a mixed solution of hydrobromic acid and acetic acid is added dropwise to the reaction liquid at -5°C to 5°C. After the addition is completed, the reaction is carried out at 20°C to 30°C for 2h to 5h to obtain the sugar compound; Wherein, the oligosaccharide compound is D-glucose, D-galactose, D-cellobiose or D-lactose.

6. The method for preparing the glycosylated pyrazole curcumin derivatives according to claim 4, characterized in that: In S1, the molar ratio of curcumin to hydrazine hydrate is 1:(1-10); and / or In S1, the molar volume ratio of curcumin to glacial acetic acid is 1 mmoL:(1-5) mL; and / or In S1, the temperature of the cyclization reaction is 90°C to 120°C.

7. The method for preparing the glycosylated pyrazole curcumin derivatives according to claim 4, characterized in that: In S2, the molar ratio of the organic base, the TBS hydroxyl protecting agent and the pyrazole curcumin represented by formula (II) is (1-4):(0.5-1.5):1; and / or In S2, the volume molar ratio of the organic solvent a to the pyrazole curcumin represented by formula (II) is (1-5) mL:1 mmoL; and / or In S2, the reaction temperature is 20°C to 40°C; and / or In S2, the organic solvent a is one or both of N,N-dimethylformamide and dimethyl sulfoxide; and / or In S2, the organic base is at least one of imidazole, pyridine or triethylamine; and / or In S2, the TBS hydroxyl protecting agent is tert-butyldimethylsilyl chloride or tert-butyldimethylsilyl trifluoromethanesulfonate.

8. The method for preparing the glycosylated pyrazole curcumin derivatives according to claim 4, characterized in that: In S3, the molar ratio of the anhydrous potassium carbonate, tetrabutylammonium bromide, sugar compound and the monohydroxy protected pyrazole curcumin represented by formula (III) is (8-30):(0.1-1):(0.8-3):1; and / or In S3, the organic solvent b is one or both of dichloromethane and acetone; and / or In S3, the volume molar ratio of the organic solvent b to the monohydroxy protected pyrazole curcumin represented by formula (III) is (10-60) mL:1 mmoL; and / or In S3, the temperature of the etherification reaction is 20°C to 40°C.

9. The method for preparing the glycosylated pyrazole curcumin derivatives according to claim 4, characterized in that: In S4, the volume molar ratio of the glacial acetic acid, the fluoride and the compound represented by formula (IV) is (0.02-0.2) mL: (0.5-2) mL: 1 mmoL; and / or In S4, the organic solvent c is anhydrous tetrahydrofuran; and / or In S4, the fluoride is tetrabutylammonium fluoride or pyridine hydrogen fluoride complex; and / or In S4, the volume molar ratio of the organic solvent c to the compound represented by formula (IV) is (5-20) mL:1 mmoL; and / or In S4, the temperature of the deprotection reaction is -10°C to 10°C; and / or In S5, the alcohol solvent is at least one of methanol, ethanol or isopropanol; and / or In S5, the volume molar ratio of the alcohol solvent to the intermediate product is (10-40) mL:1 mmoL; and / or In S5, the weak alkalinity refers to a pH of 9-10.

10. Use of the glycosylated pyrazole curcumin derivatives according to claim 1 or 2 in the preparation of anti-liver cancer or lung cancer drugs.

Citation Information

Cited By

  • Phenolic acid-sugar conjugate with blood fat reducing activity as well as preparation method and application of phenolic acid-sugar conjugate

    CN120484041A